Prospects of the clinical utilization of melatonin.
This review summarizes the present knowledge on melatonin in several areas on physiology and discusses various prospects of its clinical utilization. Ever increasing evidence indicates that melatonin has an immuno-hematopoietic role. In animal studies, melatonin provided protection against gram-negative septic shock, prevented stress-induced immunodepression, and restored immune function after a hemorrhagic shock. In human studies, melatonin amplified the antitumoral activity of interleukin-2. Melatonin has been proven as a powerful cytostatic drug in vitro as well as in vivo. In the human clinical field, melatonin appears to be a promising agent either as a diagnostic or prognostic marker of neoplastic diseases or as a compound used either alone or in combination with the standard cancer treatment. Utilization of melatonin for treatment of rhythm disorders, such as those manifested in jet lag, shift work or blindness, is one of the oldest and the most successful clinical application of this chemical. Low doses of melatonin applied in controlled-release preparation were very effective in improving the sleep latency, increasing the sleep efficiency and rising sleep quality scores in elderly, melatonin-deficient insomniacs. In the cardiovascular system, melatonin seems to regulate the tone of cerebral arteries; melatonin receptors in vascular beds appear to participate in the regulation of body temperature. Heat loss may be the principal mechanism in the initiation of sleepiness caused by melatonin. The role of melatonin in the development of migraine headaches is at present uncertain but more research could result in new ways of treatment. Melatonin is the major messenger of light-dependent periodicity, implicated in the seasonal reproduction of animals and pubertal development in humans. Multiple receptor sites detected in brain and gonadal tissues of birds and mammals of both sexes indicate that melatonin exerts a direct effect on the vertebrate reproductive organs. In a clinical study, melatonin has been used successfully as an effective female contraceptive with little side effects. Melatonin is one of the most powerful scavengers of free radicals. Because it easily penetrates the blood-brain barrier, this antioxidant may, in the future, be used for the treatment of Alzheimer's and Parkinson's diseases, stroke, nitric oxide, neurotoxicity and hyperbaric oxygen exposure. In the digestive tract, melatonin reduced the incidence and severity of gastric ulcers and prevented severe symptoms of colitis, such as mucosal lesions and diarrhea.
Bubenik
G A
GA
Department of Zoology, University of Guelph, Ont., Canada. gbubenik@uoguelph.ca
Blask
D E
DE
Brown
G M
GM
Maestroni
G J
GJ
Pang
S F
SF
Reiter
R J
RJ
Viswanathan
M
M
Zisapel
N
N
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D003278:Contraceptives, Oral, Hormonal; D016207:Cytokines / Q000378:metabolism; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006131:Growth Inhibitors / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008550:Melatonin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy; D018384:Oxidative Stress; D010870:Pineal Gland / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000502:physiology; D044094:Receptors, Melatonin; D012772:Shock, Septic / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014714:Vertebrates / Q000502:physiology
D000276:Adjuvants, Immunologic; D018931:Antineoplastic Agents, Hormonal; D000975:Antioxidants; D003278:Contraceptives, Oral, Hormonal; D016207:Cytokines; D016166:Free Radical Scavengers; D006131:Growth Inhibitors; D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin; D008550:Melatonin